Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
45,497
archived clinical trials in
Breast Cancer

Study Comparing Whole Breast Radiotherapy With a Daily Versus a Weekly Tumor
Phase III Study Comparing Whole Breast Radiotherapy With a Daily Versus a Weekly Tumor
Status: Archived
Tisch Hospital
mi
from
New York, NY
Study Comparing Whole Breast Radiotherapy With a Daily Versus a Weekly Tumor
Phase III Study Comparing Whole Breast Radiotherapy With a Daily Versus a Weekly Tumor
Status: Archived
Updated: 1/1/1970
Tisch Hospital
mi
from
New York, NY
Study Comparing Whole Breast Radiotherapy With a Daily Versus a Weekly Tumor
Phase III Study Comparing Whole Breast Radiotherapy With a Daily Versus a Weekly Tumor
Status: Archived
Bellevue Hospital Center
mi
from
New York, NY
Study Comparing Whole Breast Radiotherapy With a Daily Versus a Weekly Tumor
Phase III Study Comparing Whole Breast Radiotherapy With a Daily Versus a Weekly Tumor
Status: Archived
Updated: 1/1/1970
Bellevue Hospital Center
mi
from
New York, NY
Acupuncture for the Treatment of Chronic Lymphedema
Acupuncture for the Treatment of Chronic Lymphedema: A Feasibility Study
Status: Archived
Memorial Sloan Kettering
mi
from
New York City, NY
Acupuncture for the Treatment of Chronic Lymphedema
Acupuncture for the Treatment of Chronic Lymphedema: A Feasibility Study
Status: Archived
Updated: 1/1/1970
Memorial Sloan Kettering
mi
from
New York City, NY
18F-FLT-PET in Breast Cancer (0000-139)
A Pilot Study to Evaluate the Correlation Between 18F-FLT-PET Uptake, Ki-67 Immunohistochemistry, and Proliferation Signature in Response to Neo-Adjuvant Chemotherapy in Breast Cancer
Status: Archived
Abington Memorial Hospital
mi
from
Abington, PA
18F-FLT-PET in Breast Cancer (0000-139)
A Pilot Study to Evaluate the Correlation Between 18F-FLT-PET Uptake, Ki-67 Immunohistochemistry, and Proliferation Signature in Response to Neo-Adjuvant Chemotherapy in Breast Cancer
Status: Archived
Updated: 1/1/1970
Abington Memorial Hospital
mi
from
Abington, PA
18F-FLT-PET in Breast Cancer (0000-139)
A Pilot Study to Evaluate the Correlation Between 18F-FLT-PET Uptake, Ki-67 Immunohistochemistry, and Proliferation Signature in Response to Neo-Adjuvant Chemotherapy in Breast Cancer
Status: Archived
Clinical Research Facility
mi
from
Springfield, MA
18F-FLT-PET in Breast Cancer (0000-139)
A Pilot Study to Evaluate the Correlation Between 18F-FLT-PET Uptake, Ki-67 Immunohistochemistry, and Proliferation Signature in Response to Neo-Adjuvant Chemotherapy in Breast Cancer
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Springfield, MA
Positron Emission Tomography in Monitoring Treatment Response in Women With Newly Diagnosed Breast Cancer
Monitoring Treatment Response in Women With Breast Cancer Utilizing FLT-PET/CT
Status: Archived
Abamson Cancer Center of the University of Pennsylvania
mi
from
Philadelphia, PA
Positron Emission Tomography in Monitoring Treatment Response in Women With Newly Diagnosed Breast Cancer
Monitoring Treatment Response in Women With Breast Cancer Utilizing FLT-PET/CT
Status: Archived
Updated: 1/1/1970
Abamson Cancer Center of the University of Pennsylvania
mi
from
Philadelphia, PA
Study to Evaluate the Diagnostic Value of a Combined Molecular Breast Imaging/ Breast Tomosynthesis Modality
Pilot Study to Evaluate the Incremental Diagnostic Value of a Combined Molecular Breast Imaging / Breast Tomosynthesis Modality
Status: Archived
Mayo Clinic College of Medicine
mi
from
Rochester, MN
Study to Evaluate the Diagnostic Value of a Combined Molecular Breast Imaging/ Breast Tomosynthesis Modality
Pilot Study to Evaluate the Incremental Diagnostic Value of a Combined Molecular Breast Imaging / Breast Tomosynthesis Modality
Status: Archived
Updated: 1/1/1970
Mayo Clinic College of Medicine
mi
from
Rochester, MN
Effect of Surgery and Radiation Therapy on Tc-99M Sestamibi Uptake Patterns in Molecular Breast Imaging
Effect of Surgery and Radiation Therapy on Tc-99M Sestamibi Uptake Patterns in Molecular Breast Imaging
Status: Archived
Mayo Clinic Rochester
mi
from
Rochester, MN
Effect of Surgery and Radiation Therapy on Tc-99M Sestamibi Uptake Patterns in Molecular Breast Imaging
Effect of Surgery and Radiation Therapy on Tc-99M Sestamibi Uptake Patterns in Molecular Breast Imaging
Status: Archived
Updated: 1/1/1970
Mayo Clinic Rochester
mi
from
Rochester, MN
Study to Assess Effect of 8 Wks of Duloxetine Therapy on Breast Cancer Patients With Aromatase-Inhibitor Associated Pain
UMCC 2008.62: Prospective Pilot Study Evaluating the Use of Duloxetine for Treatment of Aromatase Inhibitor-associated Musculoskeletal Symptoms in Breast Cancer Patients
Status: Archived
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
Study to Assess Effect of 8 Wks of Duloxetine Therapy on Breast Cancer Patients With Aromatase-Inhibitor Associated Pain
UMCC 2008.62: Prospective Pilot Study Evaluating the Use of Duloxetine for Treatment of Aromatase Inhibitor-associated Musculoskeletal Symptoms in Breast Cancer Patients
Status: Archived
Updated: 1/1/1970
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
Overcoming Obstacles to Clinical Trials Enrollment Through a Navigator Program
Overcoming Obstacles to Clinical Trials Enrollment Through a Navigator Program
Status: Archived
Stanford university Hospital and Clinics
mi
from
Stanford, CA
Overcoming Obstacles to Clinical Trials Enrollment Through a Navigator Program
Overcoming Obstacles to Clinical Trials Enrollment Through a Navigator Program
Status: Archived
Updated: 1/1/1970
Stanford university Hospital and Clinics
mi
from
Stanford, CA
Trial of Amrubicin as Treatment for Patients With HER2-Negative Metastatic Breast Cancer
Phase I/II Trial of Amrubicin as Second- or Third-Line Treatment for Patients With HER2-Negative Metastatic Breast Cancer
Status: Archived
Florida Cancer Specialists
mi
from
Fort Myers, FL
Trial of Amrubicin as Treatment for Patients With HER2-Negative Metastatic Breast Cancer
Phase I/II Trial of Amrubicin as Second- or Third-Line Treatment for Patients With HER2-Negative Metastatic Breast Cancer
Status: Archived
Updated: 1/1/1970
Florida Cancer Specialists
mi
from
Fort Myers, FL
Trial of Amrubicin as Treatment for Patients With HER2-Negative Metastatic Breast Cancer
Phase I/II Trial of Amrubicin as Second- or Third-Line Treatment for Patients With HER2-Negative Metastatic Breast Cancer
Status: Archived
Northeast Georgia Heart Center, PC
mi
from
Gainesville, FL
Trial of Amrubicin as Treatment for Patients With HER2-Negative Metastatic Breast Cancer
Phase I/II Trial of Amrubicin as Second- or Third-Line Treatment for Patients With HER2-Negative Metastatic Breast Cancer
Status: Archived
Updated: 1/1/1970
Northeast Georgia Heart Center, PC
mi
from
Gainesville, FL
Trial of Amrubicin as Treatment for Patients With HER2-Negative Metastatic Breast Cancer
Phase I/II Trial of Amrubicin as Second- or Third-Line Treatment for Patients With HER2-Negative Metastatic Breast Cancer
Status: Archived
Tennessee Oncology, PLLC
mi
from
Nashville, TN
Trial of Amrubicin as Treatment for Patients With HER2-Negative Metastatic Breast Cancer
Phase I/II Trial of Amrubicin as Second- or Third-Line Treatment for Patients With HER2-Negative Metastatic Breast Cancer
Status: Archived
Updated: 1/1/1970
Tennessee Oncology, PLLC
mi
from
Nashville, TN
A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer
A Phase 2, Open-Label Study of EZN-2208 (PEG-SN38) in Patients With Previously Treated Metastatic Breast Cancer (MBC)
Status: Archived
Clinical Research Facility
mi
from
Sedona, AZ
A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer
A Phase 2, Open-Label Study of EZN-2208 (PEG-SN38) in Patients With Previously Treated Metastatic Breast Cancer (MBC)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Sedona, AZ
A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer
A Phase 2, Open-Label Study of EZN-2208 (PEG-SN38) in Patients With Previously Treated Metastatic Breast Cancer (MBC)
Status: Archived
Clinical Research Facility
mi
from
Tucson, AZ
A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer
A Phase 2, Open-Label Study of EZN-2208 (PEG-SN38) in Patients With Previously Treated Metastatic Breast Cancer (MBC)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Tucson, AZ
A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer
A Phase 2, Open-Label Study of EZN-2208 (PEG-SN38) in Patients With Previously Treated Metastatic Breast Cancer (MBC)
Status: Archived
Clinical Research Facility
mi
from
Denver, CO
A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer
A Phase 2, Open-Label Study of EZN-2208 (PEG-SN38) in Patients With Previously Treated Metastatic Breast Cancer (MBC)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Denver, CO
A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer
A Phase 2, Open-Label Study of EZN-2208 (PEG-SN38) in Patients With Previously Treated Metastatic Breast Cancer (MBC)
Status: Archived
Clinical Research Facility
mi
from
Ocoee, FL
A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer
A Phase 2, Open-Label Study of EZN-2208 (PEG-SN38) in Patients With Previously Treated Metastatic Breast Cancer (MBC)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Ocoee, FL
A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer
A Phase 2, Open-Label Study of EZN-2208 (PEG-SN38) in Patients With Previously Treated Metastatic Breast Cancer (MBC)
Status: Archived
Clinical Research Facility
mi
from
Carmel, IN
A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer
A Phase 2, Open-Label Study of EZN-2208 (PEG-SN38) in Patients With Previously Treated Metastatic Breast Cancer (MBC)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Carmel, IN
A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer
A Phase 2, Open-Label Study of EZN-2208 (PEG-SN38) in Patients With Previously Treated Metastatic Breast Cancer (MBC)
Status: Archived
Clinical Research Facility
mi
from
Minneapolis, MN
A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer
A Phase 2, Open-Label Study of EZN-2208 (PEG-SN38) in Patients With Previously Treated Metastatic Breast Cancer (MBC)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Minneapolis, MN
A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer
A Phase 2, Open-Label Study of EZN-2208 (PEG-SN38) in Patients With Previously Treated Metastatic Breast Cancer (MBC)
Status: Archived
Clinical Research Facility
mi
from
Columbia, MO
A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer
A Phase 2, Open-Label Study of EZN-2208 (PEG-SN38) in Patients With Previously Treated Metastatic Breast Cancer (MBC)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Columbia, MO
A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer
A Phase 2, Open-Label Study of EZN-2208 (PEG-SN38) in Patients With Previously Treated Metastatic Breast Cancer (MBC)
Status: Archived
Clinical Research Facility
mi
from
Kansas City, MO
A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer
A Phase 2, Open-Label Study of EZN-2208 (PEG-SN38) in Patients With Previously Treated Metastatic Breast Cancer (MBC)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Kansas City, MO
A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer
A Phase 2, Open-Label Study of EZN-2208 (PEG-SN38) in Patients With Previously Treated Metastatic Breast Cancer (MBC)
Status: Archived
Clinical Research Facility
mi
from
Henderson, NV
A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer
A Phase 2, Open-Label Study of EZN-2208 (PEG-SN38) in Patients With Previously Treated Metastatic Breast Cancer (MBC)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Henderson, NV
A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer
A Phase 2, Open-Label Study of EZN-2208 (PEG-SN38) in Patients With Previously Treated Metastatic Breast Cancer (MBC)
Status: Archived
Clinical Research Facility
mi
from
Troy, NY
A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer
A Phase 2, Open-Label Study of EZN-2208 (PEG-SN38) in Patients With Previously Treated Metastatic Breast Cancer (MBC)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Troy, NY
A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer
A Phase 2, Open-Label Study of EZN-2208 (PEG-SN38) in Patients With Previously Treated Metastatic Breast Cancer (MBC)
Status: Archived
Clinical Research Facility
mi
from
Raleigh, NC
A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer
A Phase 2, Open-Label Study of EZN-2208 (PEG-SN38) in Patients With Previously Treated Metastatic Breast Cancer (MBC)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Raleigh, NC
A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer
A Phase 2, Open-Label Study of EZN-2208 (PEG-SN38) in Patients With Previously Treated Metastatic Breast Cancer (MBC)
Status: Archived
Clinical Research Facility
mi
from
Eugene, OR
A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer
A Phase 2, Open-Label Study of EZN-2208 (PEG-SN38) in Patients With Previously Treated Metastatic Breast Cancer (MBC)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Eugene, OR
A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer
A Phase 2, Open-Label Study of EZN-2208 (PEG-SN38) in Patients With Previously Treated Metastatic Breast Cancer (MBC)
Status: Archived
Clinical Research Facility
mi
from
Portland, OR
A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer
A Phase 2, Open-Label Study of EZN-2208 (PEG-SN38) in Patients With Previously Treated Metastatic Breast Cancer (MBC)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Portland, OR
A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer
A Phase 2, Open-Label Study of EZN-2208 (PEG-SN38) in Patients With Previously Treated Metastatic Breast Cancer (MBC)
Status: Archived
Clinical Research Facility
mi
from
Kingston, PA
A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer
A Phase 2, Open-Label Study of EZN-2208 (PEG-SN38) in Patients With Previously Treated Metastatic Breast Cancer (MBC)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Kingston, PA
A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer
A Phase 2, Open-Label Study of EZN-2208 (PEG-SN38) in Patients With Previously Treated Metastatic Breast Cancer (MBC)
Status: Archived
Clinical Research Facility
mi
from
Greenville, SC
A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer
A Phase 2, Open-Label Study of EZN-2208 (PEG-SN38) in Patients With Previously Treated Metastatic Breast Cancer (MBC)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Greenville, SC
A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer
A Phase 2, Open-Label Study of EZN-2208 (PEG-SN38) in Patients With Previously Treated Metastatic Breast Cancer (MBC)
Status: Archived
Clinical Research Facility
mi
from
Austin, TX
A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer
A Phase 2, Open-Label Study of EZN-2208 (PEG-SN38) in Patients With Previously Treated Metastatic Breast Cancer (MBC)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Austin, TX
A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer
A Phase 2, Open-Label Study of EZN-2208 (PEG-SN38) in Patients With Previously Treated Metastatic Breast Cancer (MBC)
Status: Archived
Clinical Research Facility
mi
from
Bedford, TX
A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer
A Phase 2, Open-Label Study of EZN-2208 (PEG-SN38) in Patients With Previously Treated Metastatic Breast Cancer (MBC)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Bedford, TX
A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer
A Phase 2, Open-Label Study of EZN-2208 (PEG-SN38) in Patients With Previously Treated Metastatic Breast Cancer (MBC)
Status: Archived
Clinical Research Facility
mi
from
Dallas, TX
A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer
A Phase 2, Open-Label Study of EZN-2208 (PEG-SN38) in Patients With Previously Treated Metastatic Breast Cancer (MBC)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Dallas, TX
A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer
A Phase 2, Open-Label Study of EZN-2208 (PEG-SN38) in Patients With Previously Treated Metastatic Breast Cancer (MBC)
Status: Archived
Clinical Research Facility
mi
from
Dallas, TX
A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer
A Phase 2, Open-Label Study of EZN-2208 (PEG-SN38) in Patients With Previously Treated Metastatic Breast Cancer (MBC)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Dallas, TX
A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer
A Phase 2, Open-Label Study of EZN-2208 (PEG-SN38) in Patients With Previously Treated Metastatic Breast Cancer (MBC)
Status: Archived
Clinical Research Facility
mi
from
Dallas, TX
A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer
A Phase 2, Open-Label Study of EZN-2208 (PEG-SN38) in Patients With Previously Treated Metastatic Breast Cancer (MBC)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Dallas, TX
A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer
A Phase 2, Open-Label Study of EZN-2208 (PEG-SN38) in Patients With Previously Treated Metastatic Breast Cancer (MBC)
Status: Archived
Clinical Research Facility
mi
from
El Paso, TX
A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer
A Phase 2, Open-Label Study of EZN-2208 (PEG-SN38) in Patients With Previously Treated Metastatic Breast Cancer (MBC)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
El Paso, TX
A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer
A Phase 2, Open-Label Study of EZN-2208 (PEG-SN38) in Patients With Previously Treated Metastatic Breast Cancer (MBC)
Status: Archived
Clinical Research Facility
mi
from
Fort Worth, TX
A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer
A Phase 2, Open-Label Study of EZN-2208 (PEG-SN38) in Patients With Previously Treated Metastatic Breast Cancer (MBC)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Fort Worth, TX
A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer
A Phase 2, Open-Label Study of EZN-2208 (PEG-SN38) in Patients With Previously Treated Metastatic Breast Cancer (MBC)
Status: Archived
Clinical Research Facility
mi
from
Houston, TX
A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer
A Phase 2, Open-Label Study of EZN-2208 (PEG-SN38) in Patients With Previously Treated Metastatic Breast Cancer (MBC)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Houston, TX
A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer
A Phase 2, Open-Label Study of EZN-2208 (PEG-SN38) in Patients With Previously Treated Metastatic Breast Cancer (MBC)
Status: Archived
Clinical Research Facility
mi
from
Midland, TX
A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer
A Phase 2, Open-Label Study of EZN-2208 (PEG-SN38) in Patients With Previously Treated Metastatic Breast Cancer (MBC)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Midland, TX
A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer
A Phase 2, Open-Label Study of EZN-2208 (PEG-SN38) in Patients With Previously Treated Metastatic Breast Cancer (MBC)
Status: Archived
Clinical Research Facility
mi
from
San Antonio, TX
A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer
A Phase 2, Open-Label Study of EZN-2208 (PEG-SN38) in Patients With Previously Treated Metastatic Breast Cancer (MBC)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
San Antonio, TX
A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer
A Phase 2, Open-Label Study of EZN-2208 (PEG-SN38) in Patients With Previously Treated Metastatic Breast Cancer (MBC)
Status: Archived
Clinical Research Facility
mi
from
Tyler, TX
A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer
A Phase 2, Open-Label Study of EZN-2208 (PEG-SN38) in Patients With Previously Treated Metastatic Breast Cancer (MBC)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Tyler, TX
A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer
A Phase 2, Open-Label Study of EZN-2208 (PEG-SN38) in Patients With Previously Treated Metastatic Breast Cancer (MBC)
Status: Archived
Clinical Research Facility
mi
from
Fairfax, VA
A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer
A Phase 2, Open-Label Study of EZN-2208 (PEG-SN38) in Patients With Previously Treated Metastatic Breast Cancer (MBC)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Fairfax, VA
A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer
A Phase 2, Open-Label Study of EZN-2208 (PEG-SN38) in Patients With Previously Treated Metastatic Breast Cancer (MBC)
Status: Archived
Clinical Research Facility
mi
from
Norfolk, VA
A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer
A Phase 2, Open-Label Study of EZN-2208 (PEG-SN38) in Patients With Previously Treated Metastatic Breast Cancer (MBC)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Norfolk, VA
A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer
A Phase 2, Open-Label Study of EZN-2208 (PEG-SN38) in Patients With Previously Treated Metastatic Breast Cancer (MBC)
Status: Archived
Clinical Research Facility
mi
from
Salem, VA
A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer
A Phase 2, Open-Label Study of EZN-2208 (PEG-SN38) in Patients With Previously Treated Metastatic Breast Cancer (MBC)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Salem, VA
A Study of YM155 Plus Docetaxel as First-Line Treatment in Subjects With HER2 Negative Metastatic Breast Cancer
A Phase II, Multicenter, Open-Label, Randomized Study of YM155 Plus Docetaxel as First-Line Treatment in Subjects With HER2 Negative Metastatic Breast Cancer
Status: Archived
Clinical Trial Facility
mi
from
Birmingham, AL
A Study of YM155 Plus Docetaxel as First-Line Treatment in Subjects With HER2 Negative Metastatic Breast Cancer
A Phase II, Multicenter, Open-Label, Randomized Study of YM155 Plus Docetaxel as First-Line Treatment in Subjects With HER2 Negative Metastatic Breast Cancer
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Birmingham, AL
A Study of YM155 Plus Docetaxel as First-Line Treatment in Subjects With HER2 Negative Metastatic Breast Cancer
A Phase II, Multicenter, Open-Label, Randomized Study of YM155 Plus Docetaxel as First-Line Treatment in Subjects With HER2 Negative Metastatic Breast Cancer
Status: Archived
Clinical Trial Facility
mi
from
Santa Clara, CA
A Study of YM155 Plus Docetaxel as First-Line Treatment in Subjects With HER2 Negative Metastatic Breast Cancer
A Phase II, Multicenter, Open-Label, Randomized Study of YM155 Plus Docetaxel as First-Line Treatment in Subjects With HER2 Negative Metastatic Breast Cancer
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Santa Clara, CA
A Study of YM155 Plus Docetaxel as First-Line Treatment in Subjects With HER2 Negative Metastatic Breast Cancer
A Phase II, Multicenter, Open-Label, Randomized Study of YM155 Plus Docetaxel as First-Line Treatment in Subjects With HER2 Negative Metastatic Breast Cancer
Status: Archived
Clinical Trial Facility
mi
from
Celebration, FL
A Study of YM155 Plus Docetaxel as First-Line Treatment in Subjects With HER2 Negative Metastatic Breast Cancer
A Phase II, Multicenter, Open-Label, Randomized Study of YM155 Plus Docetaxel as First-Line Treatment in Subjects With HER2 Negative Metastatic Breast Cancer
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Celebration, FL
A Study of YM155 Plus Docetaxel as First-Line Treatment in Subjects With HER2 Negative Metastatic Breast Cancer
A Phase II, Multicenter, Open-Label, Randomized Study of YM155 Plus Docetaxel as First-Line Treatment in Subjects With HER2 Negative Metastatic Breast Cancer
Status: Archived
Clinical Trial Facility
mi
from
Detroit, MI
A Study of YM155 Plus Docetaxel as First-Line Treatment in Subjects With HER2 Negative Metastatic Breast Cancer
A Phase II, Multicenter, Open-Label, Randomized Study of YM155 Plus Docetaxel as First-Line Treatment in Subjects With HER2 Negative Metastatic Breast Cancer
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Detroit, MI
A Study of YM155 Plus Docetaxel as First-Line Treatment in Subjects With HER2 Negative Metastatic Breast Cancer
A Phase II, Multicenter, Open-Label, Randomized Study of YM155 Plus Docetaxel as First-Line Treatment in Subjects With HER2 Negative Metastatic Breast Cancer
Status: Archived
Clinical Trial Facility
mi
from
Great Falls, MT
A Study of YM155 Plus Docetaxel as First-Line Treatment in Subjects With HER2 Negative Metastatic Breast Cancer
A Phase II, Multicenter, Open-Label, Randomized Study of YM155 Plus Docetaxel as First-Line Treatment in Subjects With HER2 Negative Metastatic Breast Cancer
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Great Falls, MT
A Study of YM155 Plus Docetaxel as First-Line Treatment in Subjects With HER2 Negative Metastatic Breast Cancer
A Phase II, Multicenter, Open-Label, Randomized Study of YM155 Plus Docetaxel as First-Line Treatment in Subjects With HER2 Negative Metastatic Breast Cancer
Status: Archived
Clinical Trial Facility
mi
from
Albuquerque, NM
A Study of YM155 Plus Docetaxel as First-Line Treatment in Subjects With HER2 Negative Metastatic Breast Cancer
A Phase II, Multicenter, Open-Label, Randomized Study of YM155 Plus Docetaxel as First-Line Treatment in Subjects With HER2 Negative Metastatic Breast Cancer
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Albuquerque, NM
A Study of YM155 Plus Docetaxel as First-Line Treatment in Subjects With HER2 Negative Metastatic Breast Cancer
A Phase II, Multicenter, Open-Label, Randomized Study of YM155 Plus Docetaxel as First-Line Treatment in Subjects With HER2 Negative Metastatic Breast Cancer
Status: Archived
Clinical Trial Facility
mi
from
Charlotte, NC
A Study of YM155 Plus Docetaxel as First-Line Treatment in Subjects With HER2 Negative Metastatic Breast Cancer
A Phase II, Multicenter, Open-Label, Randomized Study of YM155 Plus Docetaxel as First-Line Treatment in Subjects With HER2 Negative Metastatic Breast Cancer
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Charlotte, NC
A Study of YM155 Plus Docetaxel as First-Line Treatment in Subjects With HER2 Negative Metastatic Breast Cancer
A Phase II, Multicenter, Open-Label, Randomized Study of YM155 Plus Docetaxel as First-Line Treatment in Subjects With HER2 Negative Metastatic Breast Cancer
Status: Archived
Clinical Trial Facility
mi
from
Lima, OH
A Study of YM155 Plus Docetaxel as First-Line Treatment in Subjects With HER2 Negative Metastatic Breast Cancer
A Phase II, Multicenter, Open-Label, Randomized Study of YM155 Plus Docetaxel as First-Line Treatment in Subjects With HER2 Negative Metastatic Breast Cancer
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Lima, OH